• LAST PRICE
    13.2500
  • TODAY'S CHANGE (%)
    Trending Up0.1600 (1.2223%)
  • Bid / Lots
    13.2500/ 7
  • Ask / Lots
    13.2800/ 4
  • Open / Previous Close
    13.1200 / 13.0900
  • Day Range
    Low 12.6400
    High 13.4500
  • 52 Week Range
    Low 2.3100
    High 13.9900
  • Volume
    421,901
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 13.09
TimeVolumeFUSN
09:32 ET950513.13
09:33 ET309013.26
09:35 ET929213.405
09:37 ET120013.44
09:39 ET80013.432
09:42 ET150013.425
09:44 ET706313.305
09:46 ET202013.39
09:48 ET1576513.3
09:50 ET276213.235
09:51 ET61613.23
09:53 ET471413.2
09:55 ET80013.14
09:57 ET230313.15
10:00 ET1339313.02
10:02 ET2913113
10:04 ET58512.95
10:06 ET375612.82
10:08 ET476512.855
10:09 ET335612.82
10:11 ET316812.75
10:13 ET356412.74
10:15 ET629912.85
10:18 ET90512.825
10:20 ET339812.82
10:22 ET190012.9
10:24 ET55812.89
10:26 ET374712.88
10:27 ET487812.84
10:29 ET195012.9384
10:31 ET224812.972
10:33 ET40012.98
10:36 ET90012.98
10:38 ET116312.99
10:40 ET590013.025
10:42 ET110013.04
10:44 ET115013.0589
10:45 ET41513.05
10:47 ET90013.035
10:49 ET123713.06
10:51 ET242313.07
10:54 ET30013.05
10:56 ET610013.01
10:58 ET199112.9948
11:00 ET188713.03
11:02 ET38213.045
11:03 ET216213.08
11:05 ET40013.115
11:07 ET220013.11
11:09 ET827013.14
11:12 ET196113.1914
11:14 ET20013.18
11:16 ET30013.17
11:18 ET100013.105
11:20 ET60013.0406
11:21 ET21713.08
11:23 ET213413.13
11:25 ET60013.18
11:27 ET149513.16
11:30 ET133413.1962
11:32 ET51913.18
11:34 ET387913.22
11:36 ET161313.26
11:38 ET120013.25
11:39 ET100013.25
11:41 ET350113.23
11:43 ET106613.21
11:45 ET195413.21
11:48 ET144913.17
11:50 ET20513.2139
11:52 ET127613.12
11:54 ET330113.18
11:56 ET140013.2
11:57 ET182313.22
11:59 ET141913.22
12:01 ET70013.215
12:03 ET30013.215
12:06 ET2984613.24
12:08 ET265613.235
12:10 ET328013.27
12:12 ET101813.27
12:14 ET188413.3016
12:15 ET1286513.29
12:17 ET150013.25
12:19 ET56513.27
12:21 ET185513.27
12:24 ET20013.28
12:26 ET135813.28
12:28 ET1846113.27
12:30 ET10013.26
12:32 ET127013.235
12:33 ET50013.235
12:35 ET285913.26
12:37 ET70013.28
12:39 ET80013.31
12:42 ET181713.3
12:44 ET109013.28
12:46 ET468913.294
12:48 ET20013.27
12:50 ET98413.265
12:51 ET45513.27
12:53 ET10013.26
12:55 ET240613.28
12:57 ET276713.3
01:00 ET150913.27
01:02 ET235213.215
01:04 ET155413.24
01:06 ET40013.23
01:08 ET170013.2362
01:09 ET295713.2457
01:11 ET30013.255
01:13 ET254613.27
01:15 ET10013.2501
01:18 ET70013.275
01:20 ET353313.25
01:22 ET15013.2572
01:24 ET230013.24
01:26 ET178013.24
01:27 ET90013.24
01:29 ET30013.245
01:31 ET256413.27
01:36 ET30013.24
01:40 ET60013.25
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesFUSN
Fusion Pharmaceuticals Inc
974.6M
-8.1x
---
United StatesVRDN
Viridian Therapeutics Inc
977.7M
-3.6x
---
United StatesCABA
Cabaletta Bio Inc
972.7M
-12.9x
---
United StatesZNTL
Zentalis Pharmaceuticals Inc
978.0M
-3.0x
---
United StatesCRGX
CARGO Therapeutics Inc
966.7M
0.0x
---
United StatesTYRA
Tyra Biosciences Inc
985.7M
-13.8x
---
As of 2024-02-22

Company Information

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.

Contact Information

Headquarters
270 Longwood Rd. SHAMILTON, ON, Canada L8P 0A6
Phone
289-799-0891
Fax
---

Executives

Independent Chairman of the Board
Barbara Duncan
President, Chief Business Officer
Mohit Rawat
Chief Executive Officer, Founder, Director
John Valliant
Chief Financial Officer
John Crowley
Chief Technology Officer
Eric Burak

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$974.6M
Revenue (TTM)
$2.2M
Shares Outstanding
72.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.84
EPS
$-1.63
Book Value
$3.62
P/E Ratio
-8.1x
Price/Sales (TTM)
441.4
Price/Cash Flow (TTM)
---
Operating Margin
-4,319.48%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.